Previous studies have shown that the cell cycle-regulated B-myb promoter contains a conserved E2F binding site that is critical for repressing transcription in quiescent cells. To investigate its significance for permanent promoter silencing, we have inactivated this binding site in the mouse genome. Mice homozygous for the mutant B-myb mE2F allele were fully viable, however, B-myb transcription was derepressed during quiescence in mouse embryo fibroblasts (MEFs) derived from mutant animals. Moreover, it was found that mutation of the E2F site resulted in abnormal maintenance of B-myb expression in senescent MEFs and in differentiated brain tissue. These findings therefore reveal a direct and primary role for repressive E2F complexes in silencing gene expression in post-mitotic cells. Analysis of histone modifications at the promoter showed that histone H3 lysine 9 was constitutively acetylated throughout the cell cycle in homozygous mutant MEFs. This mouse system is the first description of an E2F site mutation in situ and will facilitate the study of E2F function in vivo.
Introduction
The E2F family plays a central role in regulating transcription during the mammalian cell cycle. Individual E2F species can be categorized into activation or repression groups (reviewed by Attwooll et al. (2004) ), and this distinction depends in part upon complex formation with the retinoblastoma protein (pRb) family. Members of the activating group (E2F-1, E2F-2 and E2F-3a) transactivate a number of target genes involved in G1/S transition, and normally bind exclusively to pRb and not to the related p107 and p130 proteins. In contrast, E2F-4 and E2F-5 act predominantly to repress gene transcription during quiescence, and this activity requires p107 and p130 pocket protein interactions. The pocket proteins bind a number of chromatin modifying factors that may account for transcriptional repression by E2F complexes (reviewed by Cobrinik (2005) ). For example, pocket protein/E2F complexes recruit histone deacetylases (HDACs) to remove acetyl groups from histones H3 and H4 (Rayman et al., 2002) , resulting in a more compact chromatin structure that inhibits transcription initiation.
The B-myb gene has been subject to many studies involving E2F regulation, and the B-Myb protein is itself a transcription factor implicated in cell cycle control (reviewed by Joaquin and Watson (2003) ). We identified a critical E2F site near the B-myb transcription start site that functions primarily in transcriptional repression during G0/G1 (Lam and Watson, 1993) . Consistent with this, chromatin immunoprecipitation (ChIP) assays showed that the B-myb E2F site is occupied by E2F-4/p107 or E2F-4/p130 complexes during G0/G1. However other cell cycle-regulated promoters do not bind E2F during S phase (Zwicker et al., 1996; Takahashi et al., 2000; Wells et al., 2000) . Binding of repressive E2F complexes to the B-myb E2F site is strongly facilitated by the adjacent downstream repression site (DRS) (Bennett et al., 1996; Catchpole et al., 2002) . Although it is clear that E2F/pocket protein complexes interact with many different chromatin modifiers and even DNA methylases associated with gene repression, there is actually little direct evidence that the changes found at cell cycle-regulated promoters during cell cycle withdrawal are directed through the E2F sites. Thus, much of the evidence for E2F site dependency comes from transiently transfected promoters, which may not be correctly chromatinized. Moreover, studies of endogenous promoters in mouse cells lacking E2F and/or pocket proteins, and in human cells expressing viral oncoproteins such as E1A, are complicated by the fact that these cells suffer profound phenotypic changes affecting cell cycle regulatory processes. Previously, we generated stable NIH 3T3 cell lines carrying low copy numbers of an integrated B-myb promoter-regulated reporter and showed that the E2F site is required for recruitment of p130 and HDAC-1 to repress this gene following serum starvation (Rayman et al., 2002) . To allow investigation of promoter regulation in its natural chromatin context, we have now introduced an E2F site mutation into the endogenous B-myb promoter in mouse embryonal stem (ES) cells and have generated mice carrying this mutant allele. Importantly, this system not only allows for investigation of E2F repression in primary cells but also enables the extension of these studies to differentiated and senescent cells.
Results
Targeting the B-myb promoter E2F site in vivo To introduce a mutant B-myb promoter E2F site into the mouse germ line, a targeting vector was constructed ( Figure 1a) . A 10-kb Spe1/Pac1 DNA fragment encompassing the B-myb promoter and first and second exons was subcloned from a mouse 129/Sv strain PAC clone. First, point mutations creating a novel AflII site were introduced into the E2F site. As expected, this mutation abolished transcriptional repression when tested in a luciferase reporter assay (Figure 1b) , and was designed to allow ready discrimination of the mutated allele. Second, point mutations creating a Sma1 site in the 5 0 non-coding sequence of exon 1 were introduced to enable discrimination of transcripts from the mutant allele. A Sma1 site is present at this position in the highly homologous human B-myb sequence, and it is therefore unlikely to affect expression. Third, a neomycin resistance (neoR) cassette flanked by Flp recombinase target sites was introduced into intron 1 (Figure 1a ). The targeting vector was then electroporated into 129/Sv strain TL1 ES cells. Homologous recombination into the B-myb locus was assayed by Southern blotting of SpeI-generated genomic DNA fragments using a probe downstream of the PacI site. As a check for homologous recombination, long-range polymerase chain reaction (PCR) was carried out using primers 5 0 of the SpeI site and in intron 1. Digestion of PCR products with AflII ensured that correct recombination had occurred and also confirmed the presence of the E2F site mutation. It was found that five of six clones had the appropriate structure ( Figure 1c) .
Analysis of B-myb mRNA expression in a representative targeted ES cell clone (10G) by SmaI cleavage of reverse transcriptase (RT)-PCR products revealed that the mutated B-myb mE2Fneo allele was substantially showing the locations of the E2F site mutated by AflII restriction site substitution (mE2F site AflII), the DRS, the introduced SmaI transcript tag, restriction sites for AflII (A), BamHI (B) and EcoRI (E), exons 1 and 2 (E1 and E2) and the PGK-neo cassette cloning site. (b) Luciferase reporters containing B-myb promoters with the E2F (Afl) and SmaI mutations shown in a) were compared to the WT and mutant E2F (mE2F) B-myb promoter reporters described previously (Lam and Watson, 1993) Promoter silencing through the B-myb E2F site F Tavner et al underexpressed compared to wild type (WT) ( Figure 1d ). As this was likely due to inhibition by the neoR cassette in intron 1, this was removed by breeding B-myb þ /mE2Fneo animals with FLPe recombinase mice, thus generating the B-myb mE2F allele. B-myb þ /mE2F intercrosses produced mutant homozygotes in the expected Medelian ratio, and follow-up of these animals for over a year has not revealed any abnormalities. Expression from the mutant allele was as high, if not higher, than from the WT in mouse embryo fibroblasts (MEFs) prepared from heterozygous and homozygous B-mybmE2F animals (Figure 1d ), suggesting that neoR cassette excision fully restored transcriptional activity. Promoter silencing through the B-myb E2F site F Tavner et al re-entry kinetics were identical between WT and mutant MEFs, with S phase cells first appearing 12 h postinduction and peaking at 20 h ( Figure 2a ). Importantly, B-myb expression in mutant MEFs was significantly derepressed compared to WT in G0, and although B-myb mE2F expression was still induced by serum stimulation, the kinetics were markedly different to WT (Figure 2b ). Thus, induction of B-myb mRNA in WT cells closely paralleled entry into S phase, whereas expression in B-myb mE2F/mE2F MEFs was induced at 8 h, well before cells had entered S phase ( Figure 2b and Table 1 ). Importantly, expression of another E2F-regulated gene, cdc6, was identical in mutant and WT MEFs (Figure 2c ), indicating that deregulation of the B-myb mE2F allele was specific. To test whether the relatively low expression of B-myb expression in quiescent mutant MEFs resulted from reduced stability of the mRNA under these conditions, serum-starved and cycling B-myb mE2F/mE2F MEFs were treated with actinomycin D to prevent de novo mRNA synthesis and RNA was extracted at intervals up to 8-h postaddition ( Figure 2d ). This experiment revealed that B-myb mRNA was fairly stable in cycling cells (half-life >8 h), but turned over much more rapidly in quiescent cells (half-life approximately 5 h). This difference in mRNA stability could therefore explain why B-myb RNA levels were still inducible in mutant MEFs following re-entry into the cell cycle ( Figure 2b ).
Mutation of the endogenous
Analysis of protein expression in B-myb
MEFs showed that B-Myb was both inappropriately expressed during quiescence and overexpressed compared to WT in cycling cells (Figure 2e ). Regulation through the E2F site therefore plays a critical role during G0/G1 in extinguishing B-myb expression at both mRNA and protein levels.
The B-myb mE2F allele remains transcriptionally active in post-mitotic cells Suppression of cell cycle-regulated genes is a hallmark of senescence, and transcriptionally repressive E2F/pocket protein complexes have been implicated as critical effectors of the senescence program (Rowland et al., 2002; Narita et al., 2003) . Despite this evidence, it remains unclear whether binding of repressive E2F complexes solely dictates the silencing of cell cycleregulated genes in post-mitotic cells. Indeed, it has been argued that cellular senescence results from failure to maintain active E2F/DP required to induce expression of E2F-regulated genes (Maehara et al., 2005 Figure 3a) ; in contrast, control pBabe transductants continued proliferating until they became contact inhibited. As anticipated, B-myb mRNA expression was found to decline significantly (>5-fold) in WT cells upon senescence (Figure 3b) . A smaller 2.5-fold decline in expression was also found in senescent B-myb mE2F/mE2F
MEFs, nonetheless, mRNA levels in these cells were still comparable to cycling WT controls (Figure 3b ). Western blots showed that p21
Waf1 was expressed as expected ( Figure 3c) . In a further analysis, B-myb expression was quantitated in WT and mutant MEFs cultured under 3T3 conditions until they became senescent at passage 11. B-myb expression was reduced by >10-fold in WT MEFs, comparing passage 11 with passages 3 and 5 ( Figure 3d ). In marked contrast, B-myb expression was reduced only twofold by passage 11 in mutant MEFs and was still greater than in early passage WT MEFs (Figure 3d ). Control experiments showed that cdc6 expression was significantly reduced in both WT and mutant MEFs at passage 11 (Figure 3e ), albeit less suppression was found in mutant MEFs, which may reflect an effect of continued B-myb expression.
B-myb expression is tightly regulated during mammalian development, and in the murine central nervous system, it is lost at later stages when most cells have ceased proliferating (Sitzmann et al., 1996) . To test whether silencing would be affected by the E2F site mutation, we compared B-myb expression in brains of WT or B-myb mE2F/mE2F adult littermates and found that B-myb mRNA levels were approximately sixfold greater in mutant mice (Figure 3f ). Our findings therefore provide the first direct evidence that an E2F binding site is required for silencing of a cell cycle-regulated promoter in senescent and differentiated cells. Hence, repressive E2F complexes play the primary role in marking B-myb for permanent silencing in post-mitotic cells.
Discriminating the WT and B-myb mE2F alleles by ChIP ChIP assays have established that the WT B-myb promoter is bound in quiescent fibroblasts by a transcriptionally repressive E2F-4/p130 complex that is responsible for recruiting HDAC1 and Sin3 proteins to the promoter (Rayman et al., 2002) . It was therefore important to confirm using this technique that the Bmyb mE2F allele is unable to bind E2F-4, furthermore, these studies should allow us to obtain direct evidence that E2F complexes specify histone modifications in primary cells. Initially, heterozygous B-myb þ /mE2F MEFs made quiescent by serum deprivation were used for these analyses, as this allowed us to compare binding to the two B-myb alleles in an internally controlled manner. We discriminated between these alleles by taking advantage of the novel restriction sites in the mutant ( Figure 1a) ; as AflII did not cut the mutant allele PCR product to completion, we used SmaI for this purpose. Importantly, only the WT allele was amplified when Abbreviation: WT, wild type.
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ChIP was performed with E2F-4 antibodies (Figure 4) . In contrast, acetylated H3K9 (H3K9-ac) antibody precipitated the B-myb mE2F allele preferentially, consistent with this mark being associated with active gene transcription, whereas trimethylated H3K4 (H3K4-me3) antibody precipitated both alleles equally, consistent with the presence of this mark at both poised and actively transcribed promoters (reviewed by Margueron et al. (2005) ). Further attempts were also made to detect trimethylated H3K9, as in some studies this has been associated with E2F-dependent repression in G0 (Nielsen et al., 2001) . However, discordant results were obtained depending on the antibody source, and these results are unreliable (data not shown).
Histone H3K9 acetylation at the B-myb mE2F promoter is constant during the cell cycle To study the significance of the B-myb promoter E2F site on histone H3K9 acetylation following entry into the cell cycle, ChIP assays were performed with MEFs serum induced for 12 h post-induction, when WT B-myb mRNA levels were just starting to increase (Figure 2b ). Homozygous mutant MEFs were used in these assays, as this enabled us to quantitate the most significant data by realtime RT-PCR. As expected, E2F-4 was found only on the WT promoter (Figure 5a ), and this association was reduced at 12-h serum-stimulation concurrent with induction of transcription (Figure 2b ). Concordant with this induction, the H3K9-ac mark at the WT promoter was weak in G0 but strongly increased at 12 h. In contrast, the mutant promoter was strongly acetylated at both time points (Figure 5b ). These results imply that deacetylation of the B-myb promoter in quiescent cells is strictly dependent on a repressive E2F complex, but acetylation is presumably mediated through other transcription factor binding sites in the promoter.
Discussion
It is well established that E2F exhibits duality as both transcriptional repressor and activator, however, the (1) p3 (2) p5 (1) p5 (2) p11 (1) p11 (2) p3 (1) p3 (2) p5 (1) p5 (2) p11 (1) Promoter silencing through the B-myb E2F site F Tavner et al contributions of these two properties to cell cycle gene regulation and, in particular, to silencing of E2F-regulated genes in post-mitotic cells was still open to question. For example, certain studies have suggested that senescence results from suppression of cell cycle genes by repressive E2F complexes, whereas others lead to an alternative conclusion that senescence results from failure of activating E2Fs to maintain cell cycle gene transcription (Rowland et al., 2002; Maehara et al., 2005) . This discordance has likely arisen because the methods used in these studies to interrupt E2F/pocket protein function, whether this was by gene knockout, expression of dominant-interfering alleles or RNA interference, cause global changes in cell cycle gene expression that have profound effects upon cell phenotype. In our approach, we have affected the expression of only one gene, and it is evident from the normal phenotype of the targeted mice that this did not result in gross phenotypic alterations. This study has allowed us to conclude definitively that silencing of B-myb in postmitotic cells is dependent upon binding of repressive E2F complexes. Although we cannot formally rule out the possibility that activating E2Fs bind to other sites within the B-myb promoter, this does not deflect from the obvious conclusion that an E2F binding site orchestrates silencing of this gene. The B-myb mE2F allele therefore provides a counterpoint for future studies to investigate how silencing is brought about by repressive E2F complexes during cell cycle arrest, senescence and terminal differentiation.
Our results showed that B-myb mRNA levels in B-myb mE2F/mE2F MEFs were substantially reduced in G0 compared to S phase (Figure 2b ), despite abolition of transcriptional repression through the E2F site. It is notable, however, that the mutant allele was induced significantly earlier than WT upon re-entry into cycle following serum re-addition (Table 1) . Very similar results were obtained with p107 (Hurford et al., 1997) , indicating that repressive E2F complexes normally hold the B-myb promoter in a transcriptionally repressed state until late in G1. Although in principle the fact that B-myb mE2F transcripts levels were still serum inducible could suggest that the promoter contains growth-or mitogen-regulated elements that act independently of E2F, our previous studies using stable transfectants carrying B-myb promoter reporters indicate that the mutated promoter is fully active in G0 . Significantly, we found that the stability of the B-myb mRNA was considerably reduced under conditions of serum starvation ( Figure 2d ) and it is therefore likely that reduction of B-myb mRNA levels in quiescent B-myb mE2F/mE2F
MEFs results from this effect. Reduced mRNA stability could also account for the slight reduction in B-myb 
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(1) (2) ChIP ( ChIP assays using B-myb þ /mE2F MEFs to discriminate between proteins associated with the WT and mutant (mE2F) alleles. (a) ChIP assays were carried out with antibodies directed to E2F-4, GAL4 (irrelevant: irr), histone H3K9 (acetyl), histone H3K4 (trimethyl) and unmodified histone H3 as indicated. Radiolabelled PCR products from these assays and input (0.5%) controls were digested with SmaI before resolution of the WT and mE2F allele fragments on agarose gels and detection by phosphorimaging. (b) The relative enrichment of the mE2F allele compared to the WT was calculated from the phosphorimaging data for the E2F-4, H3K9-ac, H3K4-me3 and H3 antibodies.
Promoter silencing through the B-myb E2F site F Tavner et al mRNA levels observed in senescent mutant MEFs (Figure 3d ). It has been reported that B-myb expression was not deregulated in MEFs lacking both E2F-4 and E2F-5 genes (Gaubatz et al., 2000) , suggesting that in the absence of E2F-4/5 other E2F species (e.g. E2F-1, E2F-3 or E2F-6) can bind the promoter during G0/G1 as components of repressive complexes. In this respect, it is surprising that results from both in vivo footprinting and ChIP analyses concur that the B-myb promoter E2F site is unoccupied in S phase (Zwicker et al., 1996; Takahashi et al., 2000; Wells et al., 2000) , and this singular feature suggests that E2F species are prevented from binding at this stage of the cell cycle. Our previous findings suggest that the DRS motif adjacent to the E2F site contributes to this blockade . These observations imply that chromatin conformation around the E2F site regulates its occupancy during the cell cycle, and it will be of great interest in future studies to investigate nucleosome dynamics within the B-myb promoter. The availability of cell lines containing an E2F site mutation will provide an excellent model system for these studies.
Homozygous B-myb mE2F/mE2F mice were born in the expected Mendelian ratio and have suffered no overt defects when followed over an 18-month period. It is not surprising to find that deregulated B-myb expression is without consequence during early development, as repressive E2F complexes are absent and B-myb is very highly expressed in embryonal cells (Sitzmann et al., 1996) . It has been suggested, however, that neuronal apoptosis results when E2F repressive activity is deregulated, and that this can be mediated through B-Myb overexpression (Liu and Greene, 2001 ). Although we have yet to examine whether the failure to silence B-myb expression in the brains of B-myb mE2F/mE2F mice ( Figure 3f ) led to increased apoptosis, neuronal defects were not apparent. B-myb activity is regulated not only at the transcriptional level, but also positively by post-translational modification by cyclin-dependent kinases, in particular cyclin A/cdk2 (Robinson et al., 1996; Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997) . It is likely, therefore, that the B-Myb protein made inappropriately in post-mitotic cells of B-myb mE2F/mE2F mice is not activated, as the cyclin A gene is also an E2F target and would be silenced. Consequently, B-Myb overexpressed in mutant mouse brains would be transcriptionally inactive and possibly unable to induce neuronal apoptosis. Such restriction on B-Myb activity would ensure that it could function as an oncoprotein only under conditions where E2F-target genes are generally deregulated, a situation that occurs commonly in cancer cells through inactivation of the Rb pathway.
We have described a mouse model system in which E2F-regulation of the B-myb gene is specifically deregulated by mutation of a single E2F binding site in the promoter. This system will facilitate further studies of the factors that are required to silence cell cycle-regulated genes during senescence and differentiation.
Materials and methods
Generation and maintenance of B-myb mE2F knock-in mice A 10-kb SpeI/PacI fragment containing the B-myb promoter and exons 1 and 2 was subcloned from a mouse129/Sv genomic DNA PAC clone (UK HGMP Resource Centre, Cambridge, UK). Details of the construction of the targeting vector (Figure 1a) can be obtained from the authors upon request. The targeting construct was linearized with NotI and electroporated into TL1 ES cells. Primary screening of G418-selected (280 mg/ml) ES cell clones was performed by Southern hybridization using a PCR-generated B-myb intron 2 probe (a gift from Dr P Garcia, Birmingham University, UK). Secondary screening of putative positive ES cell clones was performed by long-range PCR using Herculase Hotstart DNA polymerase (Stratagene, La Jolla, CA, USA) with B-myb primers (CCAAGGCCACCTCCCATCTC and CGCTTTCA GACTCCCGGG), and the resultant PCR product (4787 bp) was digested with AflII to reveal correctly targeted clones. A single mouse lineage (10G) carrying the B-myb mE2F mutation was generated. Mice were maintained on a C57BL/ 6 Â 129/Sv genetic background. Genotyping was performed by PCR using primers spanning the introduced point mutations (ACGCTTCGCCCCTTCCGTATG and ATCCCCATCTCA CGCTTGCC) and the 362 bp product was digested with AflII or SmaI. Primers GAATGTCTCCCCTTGTCGCAGC and GGCTTCTGAAACCAAACCGAACC were used to genotype for removal of the phosphoglycerate kinase (PGK)-neo cassette from B-myb intron 1.
Cell culture, synchronization and flow cytometry MEFs were prepared from E12.5 to E13.5 embryos and cultured according to standard techniques (Nagy et al., 2003) . For synchronization of cultures, passage 5 MEFs were washed with unsupplemented Dulbecco's modified Eagle's medium (DMEM), starved for 72 h in DMEM containing 0.1% fetal calf serum (FCS) and restimulated by addition of DMEM/ 10% FCS. NIH 3T3 cells were maintained in DMEM supplemented with 10% newborn calf serum and made quiescent by serum starvation for 48 h in DMEM/0.5% FCS. Human embryonic kidney 293T cells were maintained in DMEM/10% FCS. Flow cytometry was performed on ethanol-fixed cells stained with propidium iodide using a FACSort analyser and CELLQuest software (Becton Dickinson, San Jose, CA, USA). FlowJo (Tree Star Inc., Ashland, OR, USA) software was used to model the flow cytometry data.
B-myb promoter/reporter assay The pGL2-(À536) and pGL2-(À536)mut B-myb promoter reporters have been described (Lam and Watson, 1993) . B-myb promoter reporters carrying targeting vector mutations (mE2F/AflII and/or transcript tag/SmaI) were subcloned into pGL2-basic (Promega, Madison, WI, USA). Reporters (0.33 mg) were co-transfected in triplicate with a b-galactosidase control vector (0.13 mg) into NIH 3T3 cells, seeded the previous day at 7 Â 10 4 /well in 24-well plates, using 2 ml Lipofectamine 2000 in OptiMEM (Invitrogen, Paisley, UK). After 5-h incubation with liposomes, the medium was replaced with DMEM/0.5% FCS for 48 h.
RNA extraction and RT-PCR RNA was extracted from cultured cells using the RNeasy kit and from 100 mg adult mouse brain using the RNeasy Lipid kit (Qiagen, Crawley, UK). Dissected brains were rinsed in PBS and chopped into slices (o0.5 cm thick) before storage in Promoter silencing through the B-myb E2F site F Tavner et al RNAlater reagent (Qiagen). First-strand cDNA synthesis was carried out using 1 mg RNA and Omniscript Reverse Transcriptase (Qiagen), followed by PCR amplification using HotStarTaq DNA polymerase (Qiagen) and B-myb primers (CCTGCAGACACGCTGACGC and TGCTGGTCTGTG CGGTTAGGA). The 3 0 primer was used to prime cDNA synthesis. The 341-bp PCR product was digested with SmaI to detect the B-myb mE2F transcript tag. A control B-myb cDNA clone containing the SmaI transcript tag was created from pMB21 (Lam et al., 1992) by PCR-based mutagenesis.
Quantitative RT-PCR One-step real-time RT-PCR was performed using the QuantiTect SYBR Green RT-PCR kit (Qiagen) on an ABI Prism 7700 Sequence Detector. Each sample was analysed in triplicate and B-myb and cdc6 mRNA expression was quantitated relative to ARPP P0 mRNA expression using the following primer sets; B-myb (AACAGTGGACGCTGATAGCCA and TTCACAGCATTGTCCGTCCTC), cdc6 (AATCCATCCTG CTGAATTGC and ATACATCCTGCCCTTTGCTG), ARPP P0 (CAAGAACACCATGATGCGCA and GCCAACAGCA TATCCCGAATC).
Western blot analysis
Whole cell lysates were prepared in buffer (500 mM NaCl, 100 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid pH7.4, 5 mM MgCl 2 , 0.5 mM ethylenediaminetetraacetic acid (EDTA), 5 mM NaF, 35% glycerol, 1 mM dithiothreitol) containing Complete protease inhibitor cocktail (Roche, Mannheim, Germany), subjected to three rounds of freezethaw and clarified by ultracentrifugation. Proteins (40 mg) were resolved by sodium dodecylsulfate (SDS)-polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane and Western blotting was performed using standard techniques with the following primary antibodies: B-Myb monoclonal LX015.1, Actin polyclonal A-2066 (Sigma-Aldrich, Poole, UK) and p21 monoclonal SX118 (a gift from Dr Xin Lu, Ludwig Institute, London, UK).
Retroviral transduction
Recombinant retrovirus stocks were generated by transient transfection of 293T cells using the Retrovirus Packaging Kit Eco (Takara Bio, Shiga, Japan) and the vectors pBabe-Puro (Morgenstern and Land, 1990 ) and pBabe-p21 (a gift from Dr G Peters, CRUK, London, UK). MEFs were seeded at 8 Â 10 5 /10 cm plate the day before infection then selected for 6 days with 2 mg/ml puromycin.
Induction of replicative senescence
MEFs were rendered senescent by serial cultivation with the 3T3 protocol (Todaro and Green, 1963) . Briefly, passage 2 MEFs were plated in duplicate at 1.5 Â 10 6 /10 cm plate and incubated for 3 days. Cells were then trypinized, replated at 1.5 Â 10 6 /10 cm plate and incubated for a further 3 days. This was repeated until passage 11 at which point the cells were incubated for 4 weeks with periodic replenishment of medium.
Chromatin immunoprecipitation
ChIP was carried out essentially as described (http://www.abcam.com). Approximately 1-2 Â 10 7 formaldehyde (0.75%) crosslinked cells were lysed in 500 ml buffer (50 mM Tris-HCl pH8, 10 mM EDTA, 1% SDS) containing Complete protease inhibitor cocktail (Roche) and sonicated to yield fragments of 500-600 bp median. ChIP was performed using 25 mg chromatin by overnight incubation at 41C with the following antibodies; anti-Histone H3K9 (acetyl) (Abcam ab4441, Cambridge, UK), anti-Histone H3K4 (trimethyl) (Abcam ab 8580), anti-Histone H3 (Abcam ab1791), anti-E2F-4 (Santa Cruz sc-1082X, Santa Cruz, CA, USA) and anti-GAL4 DNAbinding domain (Santa Cruz sc-510) as an irrelevant antibody control. Immune complexes were captured using 40 ml (50% slurry) sonicated salmon sperm DNA/protein A agarose (Upstate, Milton, Keynes, UK) for 1 h at 41C. ChIP PCRs were carried out in the presence of [ 32 P]dCTP with B-myb primers (ACGCTTCGCCCCTTCCGTATG and ATCCCCA TCTCACGCTTGCC). PCR products from B-myb
MEFs were digested with SmaI to distinguish between the WT and mutant alleles. Quantitative analysis was performed with triplicate samples using real-time PCR with the QuaniTect SYBR Green PCR kit (Qiagen).
